A composition for treating diabetes or diabesity comprising oxyntomodulin analog
The oxyntomodulin analog of the present invention has higher activities for GLP-1 receptor and glucagon receptor than natural oxyntamodulin, and can be suitably used for preventing or treating diabetes and diseases related thereto.
Abstract
The present invention relates to a composition to prevent or treat diabetes, diabesity, or diabetes complications including oxyntomodulin analog as an active ingredient. The oxyntomodulin analog of the present invention has higher activities for GLP-1 receptor and glucagon receptor than natural oxyntomodulin. The oxyntomodulin analog induces expansion of beta cells and increases insulin secretion in order to reduce blood sugar increased by high calories and high fat diet. In addition, the oxyntomodulin analog induces weight and dietary intake reduction, improving insulin sensitivity and maintaining blood sugar hard to control due to insulin resistance at normal range. Therefore, the oxyntomodulin analog can be suitably used for preventing or treating diabetes and diseases related thereto.